TORONTO and CHICAGO, July 14, 2021 (GLOBE NEWSWIRE) — Wesana Health Holdings Inc. (“Wesana” or the “Company”) (CSE: WESA), an emerging data driven life sciences company focused on developing innovative approaches for better understanding, protecting and improving neurological health and performance, including through the advancement of psychedelic medicines, today announced the addition of Ian…


Previous articleActive vs. Passive Coping Distinguishes Antidepressants and Psychedelics
Next articlePTSF72 – Breaking Down SB-519, with MAPS’ Ismail L. Ali